AC Immune (NASDAQ:ACIU – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.74 million for the quarter.
AC Immune Price Performance
Shares of NASDAQ ACIU opened at $2.50 on Thursday. The stock’s 50-day moving average is $2.67 and its two-hundred day moving average is $3.02. AC Immune has a 1-year low of $2.25 and a 1-year high of $4.98. The company has a market cap of $247.35 million, a price-to-earnings ratio of -5.43 and a beta of 1.30.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of AC Immune in a report on Friday, November 15th.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading
- Five stocks we like better than AC Immune
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- How Investors Can Find the Best Cheap Dividend Stocks
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
